Oct. 29, 2020 — Boston Scientific initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the Watchman FLX left atrial appendage closure (LAAC) device within a broad population of patients with non-valvular atrial fibrillation (NVAF), including those who are at low-to-moderate risk of bleeding from the use of anticoagulation.

October 28, 2020 — Northwestern Memorial Hospital is the first hospital in the United States to purchase Caption Health’s artificial intelligence (AI) technology for ultrasound, Caption AI.

The September-October 2020 digital edition of Diagnostic and Interventional Cardiology (DAIC) magazine include links to videos, comparison charts and related content.

Free access to the digital issue

Sign up for a free subscription.

 

Content in this issue includes or links to the following:

Chest X-ray, posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.

October 27, 2020 – Magnetic resonance imaging (MRI) examinations can be safely performed in patients with non-MR compatible cardiac devices, including pacemakers, abandoned pacing leads, and implantable cardioverter defibrillators (ICDs), according to a new study published in Radiology: Cardiothoracic Imaging.[1]
The Abiomed Breethe OXY-1 System has received U.S. FDA 510(k) clearance. 

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for an all-in-one, compact extracorporeal membrane oxygenation (ECMO) cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System.

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding stent system. This device is indicated for use in the iliofemoral veins in patients with symptomatic iliofemoral venous outflow obstruction, also known as deep venous obstruction.

October 23, 2020 —  Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world pulmonary embolism (PE) population, using the FlowTriever thrombectomy device from Inari Medical Inc. The FLASH Registry included high- and intermediate-risk patients, was obtained across 19 U.S. sites. 

October 23, 2020 – Results from the randomized controlled TARGET FFR trial show that while a physiology-guided percutaneous coronary intervention (PCI) optimization strategy did not achieve a significant increase in the proportion of patients with final fractional flow reserve (FFR) ≥0.90, it reduced the proportion of patients with a residual FFR ≤0.80 following PCI.

October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from computed tomography (FFR-CT) did not significantly reduce costs, but did reduce the use of invasive coronary angiography (ICA). This study was looking to confirm that FFR-CT use would result in a lowering of costs to care for patients in the U.K. National Health System (NHS).

Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect

October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable polymers are non-inferior to DES with biodegradable polymers in patients with acute coronary syndrome (ACS).
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now